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Summary Monoclonal antibodies 18H4 and 19F12 against alpha-foetoprotein (AFP) were examined by
enzyme immunoassay for binding to two forms of AFP that were separated on the basis of the reactivity with
lentil lectin (LCA). LCA-binding and LCA non-binding AFP, coated on a solid phase, reacted with 18H4 but
reactivity with the LCA-binding species was inhibited by 60% following pretreatment of the AFP with LCA.
The lectin was a very poor inhibitor of binding of 18H4 to the AFP which did not interact with LCA. In an
alternative binding assay, a polyclonal anti-AFP coated solid phase was reacted with P-galactosidase-labelled
18H4. Pre-treatment with LCA of the LCA-reactive AFP gave 56% inhibition of binding of conjugated 18H4
while little inhibition was achieved with the LCA-nonreactive AFP component. These findings show that the
epitope recognised by 18H4 is distinct from the glycan sequence that is reactive with LCA. However, the
LCA-binding oligosaccharides occur in close proximity to the 18H4 epitope in the native AFP.
Alpha-foetoprotein (AFP) is one of the major plasma Materials and methods
glycoproteins in the early foetal stage (Rouslahti & Seppala,
1979), and a useful tumour marker for some malignant AFP
neoplasms such as hepatocellular carcinomas, terato- AFP was isolated from serum of a patient with hepato- carcinomas and germ cell tumours (Abelev, 1968; Alpert et cellular carcinoma by affinity chromatography and DEAE-
al., 1968; Smith, 1970; Kurman et al., 1977). Serial Sephadex chromatography (Pharmacia Fine Chemicals measurement of the serum concentration of AFP may be Sephadex c atography phrmaia Fine Ce als, important in the follow-up of patients with chronic liver Uppsala Sweden) as described previously (Aoyagi et al.c
diseases (Nishi & Hirai, 1973; Okuda et al., 1980). The 1977). The LCA-reactive and nonreactive molecular species
serum concentration of AFP, however, also increases in of AFP were obtained by affinity chromatography with
chronic liver diseases such as hepatic cirrhosis and chronic lC p e P ch a) g
hepatitis (Rouslahti et al., 1974; Lehmann, 1976; Alpert & al., 1985).
Feller, 1978). Therefore, it would be desirable if the
molecular species of AFP occurring in hepatocellular Chemicals
carcinomas can be distinguished from those in non- Salt-free lyophilized powder of LCA (L-5880) was purchased
neoplastic liver diseases. from Sigma Chemical Co., St Louis, MO., USA.
Our previous study has shown that the chemical structures Horseradish peroxidase-labelled conjugate of goat anti-mouse
of foetal and hepatocellular carcinoma-derived AFPs are IgG was obtained from Jackson Immuno Research
almost identical except for a difference in carbohydrate Laboratories Inc. (Avondale, PA, USA). fl-D-galactoside
composition (Aoyagi et al., 1977, 1978, 1979, 1982). Several galactohydrolase was from Boeringer Mannheim Bio-
investigators have reported heterogeneous reactivity of AFP chemica (W. Germany).
with lectins (Smith et al., 1977; Bayard & Kerckaert, 1977;
Mackiewicz & Breborowicz, 1981; Miyazaki et al., 1981; Monoclonal anti-AFP antibodies
Breborowicz et al., 1981; Taketa et al., 1983) and we have Two monoclonal antibodies, designated McAb 18H4 and
recently observed that the AFP species in the serum of 19F12, were used in this stidy. The antibodies were derived
patients with hepatocellular carcinoma are distinguishable From werid of this mouse myeloma ce d
from those in non-malignant chronic liver diseases by from the hybridomas of P3U1 mouse myeloma cells and
crossed immuno-affinoelectrophoresis in the presence of Lens splenocytes of mice immumnzed with AFP purified from
culinaris agglutinin (LCA) (Aoyagi et al., 1984, 1985a, 1986). human foetal cord serum. These monoclonal antibodies were
Ths eto ha indiate an. inres of th LC-reactive........... purified from ascites fluids by affinity chromatography with
species of AFP in patients ithrea to eLu Arcacinm Protein A-Sepharose 4B (Pharmacia Fine Chemicals). 18H4 specieto al-} 1984)- patientsylatin ohepato lular charinomas t was of the IgGi subclass, and 19F12 was of the IgG2b. The (Aoyagi et al., 1984). Fucosylation of the sugar chain is the isolated immunoglobulins were pure as revelaed by sodium molecular basis for this variation of AFP (Aoyagi et al., dodecyl sulphate polyacrylamide gel electrophoresis and im- 1985a,b, 1986). However, the method with crossed immuno-
affino-electropnoresis requires a Skilfl techninque. aKeta munoelectrophoresis.
et al. (1985) have recently reported an antibody-affinity
blotting method that is able to distinguish LCA-reactive and Polyclonal anti-AFP antibody
nonreactive species of AFP at very low concentration of AFP. Polyclonal anti-AFP antibody (PcAb) was obtained by im-
Although this method is beneficial for the discrimination of munization of rabbits with pure AFP, and purified using
AFP species, it also requires skilful technique. AFP coupled-agarose column as previously described
The present work was initiated to develop a simpler (Aoyagi et al., 1977).
method to distinguish the LCA-reactive species of AFP from
the LCA-nonreactive species by enzyme immunoassay using AEP-coated polystyrene beads
monoclonal antibody.
Polystyrene beads (6.5mm in diameter, Mitsui Pharma-
Correspondence: Y. Suzuki. ceuticals Inc., Tokyo, Japan) were coated with 1 ,igml-
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degassed 50mM Tris-HCI buffer (pH7.5) containing Statistical analysis
150 mmuNaC, 1 mmMgCl2,9 1 mmCaCI2 and 0.02% NaN3 Statistical analyses were performed by using the unpaired t-
(buffer A) at 40C for 2 days. test. Data are represented as the mean +s.d.
PcAb-coatedpolystyrene beads
Results
Polystyrene beads were coated with 15pgml1 of purified
PcAb in buffer A at 4°C for one week. Figure la shows a standard curve in the control enzyme
immunoassay system with the solid phase coated with the
Galactosidase-labelled McAbJ8H4 (Conjugate 18H4) LCA-reactive species of AFP and monoclonal antibody 18H4 at various concentrations. This standard curve without
fl-D-galactoside galactohydrolase-labelled McAbl8H4 was the preincubation of the solid phase with LCA showed a
prepared by conjugation of reduced 18H4 with ,B-D-galacto- good dose-dependent relationship from 450 to 1500ngmlPl
sidase using N,N'-o-phenylenedimaleimide, as described by of the monoclonal antibody. Similar dose-dependent
Kato et al. (1976). standard curves were also obtained in the systems with the
LCA-nonreactive species of AFP as the solid phase and
Enzyme immunoassay and inhibition with LCA 18H4 (Figure lb), and in that with the solid phase LCA-
reactive species and 19F12 (Figure 1c).
Firstly, as a screening of McAbl8H4 with LCA inhibition Inhibition with LCA of the binding of 18H4 to the solid
assay, the following experimental procedures were phase AFPs was measured with the monoclonal antibody
performed. AFP-coated beads were preincubated at 4°C for at concentrations of 450, 750, 1125 and 1500ngml-1
3 h with 100pgml-I of LCA in buffer A in order to allow (Figure 2a). These concentrations were in the range over
this lectin to bind to a carbohydrate chain of the LCA- which the antibody was bound in a dose-dependent manner
reactive species of AFP. After washing with buffer A on to the solid phase (Figure la).
filter paper, pretreated beads were incubated with various The results indicated that pretreatment with LCA of the
amounts of monoclonal antibody at 4°C for 2h. The solid solid phase LCA-reactive species of AFP resulted in
phase polystyrene beads for control experiments were not approximately 60% inhibition of the binding of 18H4 to the
pretreated with LCA. The beads were then incubated at 4°C solid phase at maximum. With 19F12 only 27% inhibition
for 1 h with horseradish peroxidase-labelled goat anti-mouse was attained at maximum. Thus, 19F12 may serve as a
IgG anti-serum. The enzyme activity associated with the reference monoclonal antibody. At all 4 concentrations
solid phase was determined by measuring the absorbance at examined, the % inhibition with LCA for the binding of
492nm after incubation with H202 and o-phenylenediamine 18H4 to the solid phase LCA-reactive AFP species was
at room temperature for 30min. higher than that in the system with 19F112, and the
In control experiments, the AFP-coated beads were differences between 18H4 and 19F12 were statistically
allowed to react directly with monoclonal antibody at significant (P<0.02-P<0.001) (Figure 2a).
varying concentration which was determined using a value of When the LCA-nonreactive AFP species was used as a
E28°n-=15, and the enzyme activity associated with the solid phase, pretreatment with LCA had little effect on the
beads determined. Concentrations of monoclonal antibodies binding of 18H4 to the solid phase (Figure 2b), and the
bound to the solid phase in the control experiments were difference in the inhibitory effects of this treatment was
determined in quintuplicate and the results are presented as significant (P<0.05-P<0.001) between the systems with
the mean of triplicate values with the elimination of the two different LCA molecular species of AFP (Figure 2b).
maximum and minimum values. Concentrations of mono- Pretreatment of LCA did not affect the binding of 18H4
clonal antibodies bound to the solid phase in the inhibition to the solid phase coated with the LCA-nonreactive species
assay with LCA were measured in septuplicate and the of AFP (Figure 2c), indicating that the binding of 18H4 to a
results expressed as the mean of quintuplicate values with the solid phase was inhibited with LCA only when the solid
elimination of the maximum and minimum values. phase was coated with the LCA-reactive species of AFP.
Secondly, as a model system for the analysis of serum Figure 3a shows a standard curve in the control enzyme
samples of AFP species, the following procedures were immunoassay system with the LCA-reactive species of AFP
carried out: PcAb-coated beads were incubated with 200- trapped by PcAb-coated solid phase at indicated
2,000ngml-1 of either LCA-reactive or -nonreactive species concentrations and with fl-D-galactosidase-labelled McAb
of AFP in buffer A at 4°C for 2h in order to allow each 18H4. This standard curve without the LCA incubation of
AFP species to bind to solid phase PcAb. After washing the AFP trapped by solid phase PcAb showed a good dose-
with buffer A, these beads were incubated at 4°C for 3h dependent relationship from 200 to 2,000ngml-' of LCA-
with 100jgml- I ofLCAin bufferA inorder to allow this lectin reactive species of AFP. A similar dose-dependent standard
to bind to a carbohydrate chain of the LCA-reactive species curve was also obtained in the system with conjugate 18H4
of AFP trapped by solid phase PcAb. The solid phase and the LCA-nonreactive species of AFP trapped by solid
polystyrene beads for control experiments were not treated phase PcAb (Figure 3b).
with LCA. The beads were then incubated at 37°C for 2h Inhibition with LCA of the binding of conjugate 18H4 to
with JJ-D-galactosidase-labelled McAbl8H4. Tne enzyme the LCA-reactive species of AFP trapped by solid phase
activity associated with the solid phase was determined by PcAb was measured at AFP concentrations of 200, 400, 600,
measuring the absorbance at 405 nm after incubation with 800 and 1,000ngml-1 (Figure 4a). These AFP concentrations
p-nitrophenyl-,B-D-galactopyranoside (Nakarai Chemicals, were in the range where a good dose-dependent relation-
Ltd., Kyoto, Japan) at 37°C for 2h. ship was observed (Figure 3a). The results indicated that
In control experiments, the PcAb-coated beads were the LCA treatment for the LCA-reactive species of AFP
allowed to react with AFP at varying concentration which trapped by solid phase PcAb resulted in -~56% inhibition
was determined using a value of E28P0m= 5.3, and the of binding of LCA-reactive species of AFP to conjugate
enzyme activity associated with the beads determined. 18H4 at maximum in comparison with control experiments
Concentrations of AFP bound to the PcAb-coated solid without LCA treatment. At all 5 concentrations, the %
phase in the control experiments were determined in inhibitory effect with LCA treatment of the binding of
quintuplicate and the results were represented as the mean conjugate I18H4 to the LCA-reactive species of AFP was
of triplicate, values with the elimination of the maximum and statistically higher than that in the system without the LCA
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Figure 1 (a) Control experiments for the measurement of the antibody concentration bound to the solid phase without the
pretreatment with LCA. The polystyrene beads coated with the LCA-reactive species of AFP were incubated at 40C for 2h with
McAb 18H4 at various concentrations. After washing, the beads were immersed in horseradish peroxidase-labelled goat anti-mouse
IgG solution at 4°C for 1 h. The beads were then incubated in an H202 and o-phenylenediamine solution at room temperature for
30min and the absorbance at 492 nm was measured. The standard curve was constructed by plotting of the absorbance values on
the ordinate (arithmetic scale) against the concentration of 18H4 on the abscissa (logarithmic scale), and a computer programmed
sigmoid curve was applied. Vertical bars denote +s.d. of triplicate determinations. (b) Control experiments for the measurement
of 18H4 concentration bound to the solid phase coated with the LCA-nonreactive species of AFP without the LCA-pretreatment.
The standard curve was constructed as described in the legend for (a). (c) Control experiments for the measurement of the 19F12
concentration bound to the solid phase coated with the LCA-reactive species of AFP without the LCA-pretreatment. The standard
curve was constructed as described in the legend for (a).
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Figure 2 (a) The effects of LCA pretreatment on the binding of monoclonal antibodies to the solid phase LCA-reactive species of
AFP. LCA-reactive AFP coated polystyrene beads were pretreated with LCA (100 gml-1) at 4°C for 3h and then allowed to
react with either 18H4 (0) or 19F12 (0) at concentrations of 450, 750, 1,125 and l,SOOngml-1. The bound antibody was
quantitated as described in the legend of Figurel(a) and % inhibition was calculated by comparison with the data from control
experiments in which the LCA pretreatment was omitted. Values represent the mean +s.d. (vertical bars, n =5). The differences in
the mean % inhibition were statistically significant between the experiments with 18H4 and 19F12 at concentrations of
450 ngml 1 (P<0.02), 750 ngml - (P <0.02), 1,125 ngml - 1 (P <0.01) and 1,500 ngml - 1 (P<0.001).
Figure 2 (b) Comparison of the degree of inhibition with LCA between the binding of 18H4 to the solid phase LCA-reactive
species of AFP and that to the solid phase LCA-nonreactive species. Polystyrene beads coated with either LCA-reactive (0) or
LCA-nonreactive (0) species of AFP were incubated with LCA. The beads were then allowed to react with 18H4 at
concentrations indicated, and the bound antibody concentrations was determined as described in the legend of Figure l(a). Values
shown are the mean +s.d. (vertical bars, n=5). The difference in the mean % inhibition was statistically significant between the
experiments with the solid phase LCA-reactive and nonreactive species of AFP at each point of antibody concentrations of
450ngml 1 (P<0.05), 750ngml-1 (P<0.02), 1,125 ngml-1 (P<0.001), and 1,500ngml-1 (P<0.01).
Figure 2 (c) Effects of the LCA-pretreatment on the binding of 18H4 to the solid phase coated with the LCA-nonreactive species
of AFP. Polystyrene beads were coated with the LCA-nonreactive species of AFP. The beads treated (0) or untreated (0) with
LCA were then allowed to react with 18H4. The concentration of 18H4 bound to the beads was determined as described in the
legend of Figure l(a). Values shown are the mean +s.d. (vertical bars, n=5). No statistically significant differences were observed
in the mean % inhibition between the experiments with and without the preincubation of the solid phase with LCA at each point
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Figure 3 (a) Control experiments for the measurement of concentration of LCA-reactive species of AFP bound to the PcAb-
coated solid phase without the treatment with LCA. The PcAb-coated polystyrene beads were incubated at 37°C for 2h with
LCA-reactive species of AFP at various concentrations. After washing, the beads were immersed in a ,B-D-galactosidase-labelled
McAbl8H4 at 4°C for 2h. The beads were then incubated in p-nitrophenyl-f-D-galactopyranoside at 37°C for 2h, and the
absorbance at 405nm was measured. The standard curve was constructed by plotting of the absorbance values on the ordinate
(arithmetic scale) against the concentration of LCA-reactive species of AFP on the abscissa (logarithmic scale), and a computer
programmed sigmoid curve was applied. Vertical bars denote +s.d. of triplicate determinations. (b) Control experiments for the
measurement of concentration of LCA-noncreative species of AFP bound to the PcAb-coated polystyrene beads without the
treatment with LCA. The standard curve was constructed as described in the legend for (a).
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Figure 4 (a) Effects of LCA treatment on the binding of ,B-D-galactosidase-labelled 18H4 to the LCA-reactive species of AFP
trapped by PcAb-coated solid phase. PcAb-coated polystyrene beads were incubated with LCA-reactive species of AFP at
indicated concentrations at 37°C for 2h. After washing, the beads were treated (0) with LCA (100,gmP 1) at 4°C for 3h or
untreated (0), and were then allowed to react with conjugate 18H4. The conjugate 18H4 bound to the LCA-reactive species of
AFP was quantitated as described in the legend of Figure 3(a). Inhibition percentages were calculated by comparing with the data
from control experiments in which the LCA-treatment was omitted. Values represent the mean ±+s.d. (vertical bars, n=3). The
differences in the mean % inhibition were statistically significant between the experiments with and without LCA-treatment at
AFP concentrations of 200ngml- (P<0.001), 400ngml- (P<0.OOS), 600ngml- (P<0.001), 800ngml- (P<0.005) and
1,000 ngml- (P<0.00l). (b) Comparison of the degree of inhibition with LCA between the binding of conjugate 18H4 to the
LCA-reactive species of AFP trapped by solid PcAb and that to the LCA-nonreactive species of AFP trapped by solid phase
PcAb. PcAb-coated polystyrene beads which were incubated with either LCA-reactive (0) or LCA-nonreactive (0) species of
AFP were treated with LCA. The beads were then allowed to react with conjugate 18H4, and conjugate 18H4 bound to each AFP
species was quantitated as described in the legends of Figures 3(a) and 4(a). Inhibition % values shown are the mean +s.d.
(vertical bars, n=3), and the differences in the mean % inhibition was statistically significant between the experiments with LCA-
reactive and nonreactive species of AFP at AFP concentrations of 200ngml-' (P<0.001), 400ngml- (P<0.05), 600ngml'
(P<0.001), 800 ngmlP- (p<0.00S) and 1,000 ngmlP- (P<0O.OO5).
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When the LCA-nonreactive species of AFP was examined,
treatment with LCA had little effect on the binding of
conjugate 18H4 to the AFP trapped by solid phase PcAb
(Figure 4b), and the difference in the inhibitory effect of this
treatment was statistically significant (P<0.05-P<0.001)
for the systems with two different LCA molecular species of
AFP (Figure 4b).
Discussion
Application of the monoclonal antibody technique to the
quantitative measurement of serum markers in patients with
several diseases has been described (Wands et al., 1982;
Hedin et al., 1983). Bellet et al. (1984) recently reported the
specific radioimmunoassay method for hepatocellular
carcinoma with use of monoclonal anti-AFP antibodies
which were supposed to recognize certain unique epitopes of
AFP. They have claimed that the method is more useful
than conventional radioimmunoassays for the detection and
monitoring of AFP-producing tumours in high risk popu-
lations, and for distinguishing hepatocellular carcinomas
from nonmalignant liver diseases or healthy subjects.
We have recently found that the degree of fucosylation of
AFP is a good marker for distinguishing hepatocellular
carcinomas from nonmalignant liver diseases (Aoyagi et al.,
1984, 1985a, 1986). The fucosylated and non-fucosylated
molecular species of AFP can be measured by crossed
immuno-affinoelectrophoresis with LCA, by taking
advantage of the reactivity of the fucosylated species with
this lectin. Similar methods have been widely used for
diagnosis of neural tube defects (Smith et al., 1979; Toftager-
Larsen et al., 1983) and liver diseases (Miyazaki et al., 1981;
Breborowicz et al., 1981) with lectins such as Con A and
LCA. Recently a new attempt by immunoblotting technique
for the discrimination of AFP species has been reported by
Taketa et al. (1985).
However, the method of crossed immuno-affino-
electrophoresis and antibody-affinity blotting has certain
limitations as described above. Therefore, we aimed to
provide a more convenient method which distinguishes
between the fucosylated and non-fucosylated molecular
species of AFP.
In the present study, we prepared monoclonal antibody
18H4 for such a purpose. The binding of 18H4 to the solid
phase coated with the LCA-reactive species of AFP was
inhibited by pretreating the solid phase with LCA
(Figure 2b). Such inhibition was not observed when the solid
phase was coated with the LCA-nonreactive species of AFP
(Figure 2b). In similar experiments with monoclonal
antibody 19F12, LCA only slightly inhibited the binding of
this antibody to the solid phase coated with the LCA-
reactive species of AFP (Figure 2a).
As described above, McAbl8H4 was selected in the system
with AFP-coated solid phase. Thereafter we developed a
model system for the analysis of serum samples of AFP
species. PcAb-coated polystyrene beads were prepared, and
incubated with LCA-reactive or nonreactive (Figures 4a, b)
species of AFP at various concentrations from 200 to
2,000ngml- 1. These AFP species trapped by solid phase
PcAb were then treated with LCA, and incubated with /3-D-
galactosidase-labelled 188H4. The bound conjugate of 18H4
to AFP species was quantified, and % inhibition was
calculated by comparison with the data from control
experiments without LCA treatment. The binding of
conjugate 18H4 to the LCA-reactive species of AFP trapped
by solid phase PcAb was inhibited by treating with LCA
(Figures 4a, b). Such inhibition was not obtained when the
LCA-nonreactive species of AFP was examined in the system
with PcAb-coated polystyrene beads and with LCA treat-
ment (Figure 4b).
Inhibition of the binding of 18H4 to the LCA-reactive
species of AFP can be explained by assuming that this
monoclonal antibody recognizes an epitope of AFP which is
closely located to the attachment site of a carbohydrate
chain. (Pre)treatment with LCA of the LCA-reactive species
of AFP would result in the binding of this lectin to its
fucosylated sugar chain, and prevent 18H4 from binding to
the AFP-molecular species by steric hindrance. The reason
why complete inhibition was not achieved by the (pre)treat-
ment with LCA may be that 18H4 does not recognize a
carbohydrate chain itself.
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